ZNF154 and pancreatic neoplasm: That same study demonstrated that ZNF154 circulating-free DNA (cfDNA) methylation discriminated cases from healthy donor plasma samples and outperformed KRAS mutation frequency as a biomarker in pancreatic cancer.